ERBB2 and breast cancer: In summary, this is the first study to analyze the usefulness of the 21-gene RS according to clinical risk in the subset of patients with tumor size 1–5 cm, N0-1, HR+/HER2- breast cancer, in terms of chemotherapy rate and survival.